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challenge grant application about genetic variation in the 5-alpha reductase gene (SRD5A2) and its association with BPH.
Further collaborations have been made with researchers at the University of Washington, Seattle, WA. Dr. Torkko will be a PI on a subcontract for a grant written by Dr. Ulrike Peters that will propose to study vitamin D pathway genetic variation and correlations with diet and serum measures of vitamin D status in the Prostate Cancer Prevention Trial cohort. Dr. Torkko will be responsible for the analysis of gene-gene interactions between vitamin D and androgen pathway genes.
Dr. Torkko has taken a new direction in her health disparity research. She is collaborating with researchers and physicians in the Department of Surgery, Section of Urology, to understand health disparities in screening for prostate cancer. She is the PI on a grant submitted to the State of Colorado to increase education about and access to prostate cancer screening in rural Colorado. An important group for this outreach is Hispanic men. Decisions about funding should be completed by April 2009.
Scientific Conferences
As part of the training for the grant, Dr. Torkko is expected to attend scientific conferences chosen to be relevant to prostate cancer, genetic epidemiology, and/or health disparity/cultural competency. Funds have been allocated to attend at least one conference each funded year. In the 2008-09 grant period, Dr. Torkko attended the second American Association of Cancer Researchers conference on "The Science of Cancer Health Disparities in Racial/Ethnic Minorities and Medically Underserved" in Carefree, AZ, from February 3-6, 2009. As research data become available and analyses mature, it is expected that abstracts will be submitted for future conferences.
Based on her work with health disparities and interests in screening issues, Dr. Torkko was invited to give a lecture at an industry-sponsored meeting on the PCA3 urine test for the detection of prostate cancer. She spoke on race and screening for prostate cancer (see PowerPoint slides of the presentation in Appendix A)
Coursework
As part of the training for the grant, Dr. Torkko is expected to continue her education by taking relevant classes. Dr. Torkko took two classes within the timeframe of the second year of the grant. In the Fall semester 2008, she took two classes (syllabi in Appendix B) offered by the Department of Biostatistics and Informatics in the School of Public Health, University of Colorado.. Due to the large datasets that Dr. Torkko must manage for her data collection and analysis, she took the SAS Database Design and Management class (BIOS 6680). This course allowed Dr. Torkko to improve her SAS skills and to learn more about database design and structured query language (SQL) that allows communication between different database programs. She also took a class that taught the use of R, a free statistical program that researchers at the University of Texas Health Sciences Center San Antonio use for their genetic analyses. This class taught the use of R to analyze large, publically available datasets, specifically for gene expression datasets. She received an "A" in both classes (see transcript in Appendix C).
In the Spring semester 2008, Dr. Torkko taught the Introductory Epidemiology class (HBSC 4001/5001) for the Health and Behavior Sciences Department at the UCD. She made health disparities a focus of the class (see course syllabus in Appendix D). She had her students write a final project on a cancer of their choice about the epidemiology of the cancer and to identify an area where a health disparity exists. Dr. Torkko developed a 90-minute lecture on health disparities (see Appendix E for PowerPoint slides). Teaching this class has given Dr. Torkko invaluable experience and should lead to other teaching and career development opportunities. Development and IRB-approval has been obtained and the first mailing of the survey to study participants has been completed. The second mailing to non-responders is currently underway. Approximately 50% of SABOR participants have responded. Men who do not return the survey after the second contact will be asked to complete a form during their annual study visit. Data entry will commence in May 2009. Double entry of all forms will be done and discrepancies will resolved to ensure data entry integrity. Data analysis will be completed by the end of summer. A copy of the survey is included in the Appendix F.
Research Project Progress

Single Nucleotide Polymorphisms
Specific Aim #2: Determine whether VDR polymorphisms, haplotypes, and gene-gene interactions differ by race/ethnicity. Men will be genotyped for VDR, CYP27B1, and CYP24 polymorphisms. A genetic association case-control study will be performed looking for associations of these polymorphisms and haplotypes with prostate cancer.
The first step of the research plan was to identify a panel of ingle nucleotide polymorphisms (SNPs) for the genes of interest. With the assistance of Dr. Robin Leach at UTHSCSA, a panel of 21 VDR SNPs, and 31 SNPs in vitamin D associated genes (CYP27B1, CYP24A1, PDF) has been assembled (see Appendix G for a list of the SNPs). These SNPs were chosen as tag SNPs to identify known haplotypes in each gene. As part of her research, Dr. Leach is studying genes in the testosterone pathway and has developed an extensive panel of tagSNPs. There will be opportunities for Dr. Torkko to use these SNPs to study gene-gene interactions between vitamin D and testosterone metabolic pathway genes.
Difficulties with the new technology to genotype the panel of SNPs led to delays in genotyping. Some important SNPs failed quality control and need to be redone. A new panel is being developed using a slightly different technology for those SNPs. Additional SNPs that have appeared in the literature since the original list was chosen will be added (see Appendix G). Genotyping should be completed by the end of the summer when analysis with the completed survey can be started (see specific Aim #3). Course Description: This course provides students with hands on experience in analyzing full-scale microarray data using the statistical software R, and its packages from the Bioconductor consortium.
Course Objectives: After completion of the course, students will be able perform a complete microarray data analysis project from start to finish, including exploring the nature of the dataset, selecting significant genes for the hypothesis being tested, interpreting the biological meaning of the results, and learning to work with existing public datasets. All these will be accomplished using the free open-source statistical software R. • Homework assignments: There will be 5 problem sets for the semester.
Evaluation
• Participation: This is a hands-on statistics software course, all students will be expected to help each others in fixing bugs, as well as to solve problems using outside web resources.
• Final Project: Students will create a final project that utilize dataset from public repositories and apply what they learned from the course.
Assignments and Final Project:
Late homework is not accepted without prior permission from the instructor. Students are encouraged to work together on homework assignments, however, the assignment handed in must represent the student's own work. Students are not to work together or discuss the final project.
Software: Students will use the free open-source R statistical computation tool for all works in this course 
III. Evaluation:
Homework will be assigned each Thursday and must be handed in at the beginning of class on the following Thursday. Because I may discuss the solution to homework problems in class, no late homework will be accepted. If you must miss a class, please turn in your homework early or let me know as soon as possible so that I can assign an alternate homework problem to you.
Homework may be worked on collaboratively unless I tell you otherwise. There will be at least two assigmments that must be completed on your own. 
VII.
Accessing SAS To purchase it, go to Building 500, Room C4000. If you need directions, call x40400 or x44357
• If you purchase it now, it will be good through June 30, 2009.
• Cost is $115.
• Pay by check, money order or IN. Bring a UCDenver student ID. Use it for free in certain computing labs: ED2 P28-2201C (13 systems) or RC1 P18-1309 (24 computers )
VIII. Honor Code:
Education at the Health Sciences Center is conducted under the honor system. All students who have entered health professional programs should have developed the qualities of honesty and integrity, and each student should apply these principles to his or her academic and subsequent professional career. All students are expected to have achieved a level of maturity, which is reflected in appropriate conduct at all times. All work done on exams or other assignments is to be done independently unless specific instruction to the contrary is provided. Introduces the basic concepts of public health and epidemiology, including assessment of disease in the community, the study of causation and association of disease with lifestyle and environmental risk factors, as well as related special topics. Prereq: upper division standing and course in basic statistical methods. Cross-listed with HBSC 4001.
Instructor Description:
This is an introductory epidemiology course designed for graduate students in the Health and Behavioral Sciences (HBS) program at the University of Colorado Denver. The model for this course is the Introduction to Epidemiology (PRMD 6630) taught in the Department of Preventive Medicine and Biometrics (PMD) at the Health Sciences Center campus. This course will cover the same basic epidemiologic concepts taught in that class allowing students to take advanced epidemiology courses taught through PMD. Because epidemiology is considered part of the medical sciences and its roots come from the study of infectious disease, it is necessary to discuss the medical aspects of disease to illustrate many epidemiologic principles. It will also be necessary for students to brush up on their basic math skills. Content for this course will include some emphasis on topics that may be of more interests to HBS students as compared to the more purely medical focus of the 6630 course.
This course will provide students with an understanding of the basic methods and tools used by epidemiologists to study rates and risks for disease and other factors that affect the health of people. Epidemiologic techniques are used to study a wide variety of health concerns including infectious disease outbreaks, risk factors for chronic diseases, and societal and behavioral factors affecting access to and use of health services. This variety makes epidemiology an exciting and useful area of study. Although this course will not turn you into epidemiologists, I hope you will develop some excitement for the subject and an appreciation for the relevance of epidemiology to your areas of interest.
Epidemiology is not black-and-white. Often there is not necessarily a "right" answer. There may be many ways to study a problem and the choice of an approach will depend on the nature of the questions being asked and on such practicalities as the availability of data and costs. Sometimes we choose the best answer or one way to study a problem, although it is not necessarily the only answer nor the only way to study it. Epidemiology is often a science of compromises. This can be particularly aggravating for students who might prefer that all questions have either right or wrong answers. All this can make epidemiology a difficult subject to teach and to learn. It is possible that you may pose questions that I am not able to answer immediately, or I may change my mind after further reflection. I also expect that some of you will come up with answers that had not occurred to me. I anticipate a dialog between you and myself. Please feel free to ask questions. I look forward to teaching and learning from you.
One theme for this class is the use of epidemiologic techniques to study health disparities in populations. You will be expected to complete a final project consisting of a short paper using what was learned over the semester to describe a health disparity whether by race, gender, age, geography, socioeconomic status or other factors of interest. I have a grant to study health disparities in cancer, particularly in prostate cancer. This is a wonderful opportunity for students to teach the teacher about health disparities, particularly in prostate cancer.
To learn epidemiology, a student may need several passes through the material. It is expected that you will have read all materials and performed all tasks assigned for a particular session prior to the start of class. Reading the material in advance will help you formulate questions. My teaching style will be interactive with in-class exercises and self-assessments to facilitate in-class discussion to help me gauge now well students are learning (and how well I am explaining things!).
Because we are meeting for 3 hours, the class session will be divided into two sub-sessions, A and B, with a short break in between depending on time constraints for a particular lecture. Each session will include two separate lectures on related topics or a lecture with an in-class exercise. Much of the in-class work will require some preparation that will serve as the homework for the (sub-)session.
Handouts of the lecture slides will be posted at least 24 hours prior to each lecture so you may print them for lecture notes. Materials will be accessible on Blackboard. I will be available before each session for questions and additional help. I will try to arrive at least 30-60 minutes prior to each class session (I am a person who is usually running late!). I can make it earlier to class by appointment. Please feel free to e-mail me or call.
Course Objectives:
At the end of this course, the student will:
1. Be able to use epidemiologic terminology 2. Understand and calculate different rates and measures of association (i.e., OR, RR) 3. Articulate clearly the strengths and limitations of different epidemiologic study designs 4. Understand important epidemiologic concepts including confounding, bias, and causation 5. Be able to critically read epidemiologic literature to recognize study design and analytical strengths and limitations.
Required Text:
Gordis L. Epidemiology, 3 rd Ed., Elsevier Saunders, 2004
Assignments: Homework: Generally homework will be assigned for each sub-session. This includes working out problems, providing short answers and definitions, and reading assignments. The homework assigned will usually cover material that will be discussed at the session. Although this may seem counter-intuitive, grappling with problems and deriving your own solutions before learning how other people have done it will give you experience in solving new problems and allow you to develop a clearer view of the strengths and weaknesses of accepted solutions. Try working out problems first by yourself. If you run into difficulty, feel free to collaborate with your fellow students. But don't just copy answers. If you really don't understand something, discuss it or contact me. Homework must be submitted prior to class electronically or on hard copy at the beginning of class. Failure to do so will deduct 20% from your score (unless you have an EXCELLENT reason for being late). Graded assignments will be returned the next class session. Answers to homework will be posted on Blackboard a week after they are due.
Exams: There will be two formal exams, a midterm (on March 11) and a final (on May 12). The exams will be in-class and open book and will include multiple choice questions and short answers. Some calculations will be required so calculators will be permitted, but not computers. The midterm will cover material presented up to that point; the final will cover the entire term with an emphasis on the latter half. There will be opportunities for formal review before each exam. The first hour of the session will be given to any review questions with the latter 2 hours for the exam.
A final project will entail writing a 3-5 page paper (double-spaced) plus tables or figures. The topic will be of your choice but must cover a health disparity in Colorado, the US, or elsewhere around the world. The topic must be OK'd by me (topic must be chosen by April 1). Preference should be given to cancer, particularly prostate cancer, or another topic that is of great interest to you or your work. There will be no preferential grading given to those who pick prostate cancer, so you are free to choose as you wish. If you can't decide on a topic, I will assign one to you. For this project you will use epidemiology to describe the disparity (rates, risks, etc.) and discuss the types of studies, source of data to describe the disparity. You will briefly discuss any potential problems with the data or gaps in our knowledge. We will discuss the requirements in more detail during a class session. The paper must be submitted electronically or on hard copy by May 6.
Graded midterms will be returned the following class session. Graded final exams and projects will be available at the HBS office after May 19 th .
Grades:
Final grades will be determined on a curve and based on homework assignments, in-class exercises, two exams (midterm and final), and a final project according to the following distribution: In-class participation will also be assessed by awarding additional points based on a scale from 0-10 with "0" meaning you never opened your mouth in class to 10 meaning you participated in most if not all discussions. This means a total score of 110 points is possible, but remember, the class is graded on a curve.
Course Policies:
Class attendance and participation is essential for success. No deductions in the final grade will be applied for non-attendance (as long as assignments are turned in on time), but you will miss out on critical questions and discussions. There is no requirement to notify me if you miss class, but I would appreciate a courtesy e-mail to explain unanticipated absences.
The schedule of coursework listed below is not written in stone and may be subject to unplanned changes such as instructor or guest lecturer illness. Additionally, I reserve the right to change the syllabus depending on the needs and interests of the students. Students will be given appropriate, timely, and written notification of any changes.
Homework can either be (clearly) handwritten or typed with room in the margins for me to make comments. Homework can be submitted electronically (MS-Word) or on hard copy. When students' work conveys that they require additional help in composition or math, students will be referred to the Writing Lab and/or the Math Lab. It is your responsibility to clarify missed assignments with me. Homework not submitted in time (by the beginning of the class session) will have a 20% reduction applied to the score. Late homework not submitted by or at the beginning of the following class session will not be graded (although you will get feedback).
If you will miss a scheduled exam, you must notify me prior to the start of the exam. In cases of an emergency, you can call me on my cell phone or contact the HBS office to leave a message. A make-up exam will be re-scheduled. This should be done within a week after the date of the original exam. This may mean you will have to travel to the Anschutz Medical Campus to take the exam unless I can find someone to proctor it on the Auraria Campus. If a make-up is necessary, I ask the other students to refrain from sharing any specific information about the content of the exam with the student(s) who will be taking the make-up. What are Health Disparities?
The variation in physical, mental, or social well-being based upon gender or race/ethnicity, insurance status, treatment differences, disability, stigma, etc.
Achieving equity in health implies eliminating inequalities between social groups which are unnecessary, avoidable and therefore unjust.
Often spoken of in terms of race-ethnicity, but disparities also exist by gender, age, socio-economic status, place of residence (rural vs. urban), etc.
Model of Health Care Disparities
Non-Minority
Clinical appropriateness and need Dissimilarity
The model views health care disparities as resulting from characteristics of the health care system, the society's legal and regulatory climate, discrimination, bias, stereotyping and uncertainty. Not all dissimilarities in care are necessarily a disparity. 
Disparities in Diagnostic Care
The length of time between an abnormal screening mammogram and the follow-up diagnostic test to determine whether a woman has breast cancer is more than t i l f A i A i bl k d Hi i twice as long for Asian American, black, and Hispanic women as for white women. Many sources -including health systems, health care providers, patients, and utilization managers -contribute to racial and ethnic disparities in health care IOM Bias, stereotyping, prejudice, and clinical uncertainty on the part of healthcare providers may contribute to racial and ethnic disparities in healthcare. While indirect evidence from several lines of research supports this statement, a greater understanding of the prevalence and influence of these processes is needed and should be Unequal Treatment: Summary of Findings -cont.
influence of these processes is needed and should be sought through research.
Racial and ethnic minority patients are more likely than white patients to refuse treatment, but differences in refusal rates are generally small, and minority patient refusal does not fully explain healthcare disparities. IOM 
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General Recommendations
Increase awareness of racial and ethnic disparities in health care among the general public and key stakeholders, and increase health care providers' awareness of disparities. Prostate cancer is the most commonly diagnosed non -skin cancer and one of the 10 leading causes of death in American men (1) . The etiology of prostate cancer is not well known, although both genetic and environmental factors are believed to play a role. A twin study from Scandinavia estimated that 42% of the risk for prostate cancer might be explained by heritable factors (2) . A diverse range of foods and nutrients have been found to moderately affect risk for prostate cancer, including soy, isoflavones, milk, saturated fats, and tomato products (3) . A link between prostate cancer and vitamin D has been hypothesized. Lower levels of vitamin D in the serum have been associated with increased prostate cancer risk (4) . In vitro studies have found that treating prostate cancer cells with vitamin D inhibits cell proliferation (5). Given these observations, it has been proposed that adequate circulating levels of vitamin D are important to protect against prostate cancer.
Summary of Recommendations
The androgen testosterone and its bioactive form, dihydrotestosterone (DHT), are necessary for the normal growth and development of the prostate, and epidemiologic evidence supports their role in the etiology of prostate cancer (6) . 5a-Reductase type II is the primary enzyme that converts testosterone to DHT in the prostate (7) . Men who lack the gene that codes for 5a-reductase type II have low DHT levels Cancer Prevention and Susceptibility and small prostates (8) . Finasteride, an inhibitor of 5a-reductase type II, reduces the growth of cells from the androgen-dependent LNCaP prostate cancer cell line (9) and is associated with a decrease in tissue DHT levels (10) . The Prostate Cancer Prevention Trial showed that men given finasteride had a 24.8% reduction in cancer prevalence over 7 years compared with men given placebo (11) . Increased expression of 5a-reductase type II is also associated with recurrent and metastatic prostate cancer implying a role for the enzyme and DHT in prostate cancer progression (12) . The growth and differentiation of normal prostatic tissue is promoted by interactions between the vitamin D and DHT pathways (13) . Levels of the bioactive form of vitamin D, calcitriol, are controlled in an autocrine fashion to regulate cell growth and decrease the risk of the cells becoming malignant. DHT seems to act as a regulator of vitamin D activity. When cells from the prostate cancer cell line LNCaP are grown in androgen-depleted medium, vitamin D no longer inhibits cell growth. With the addition of DHT, even at low physiologic levels (1 nmol/L), the antiproliferative effects of vitamin D are restored (14) . It was later shown that this effect is mediated by DHT-induced suppression of 24-hydroxylase expression, the enzyme that inactivates calcitriol (15) and its precursor form (14) . Additionally, in two androgen receptor -positive prostate cancer cell lines (DHT binds to androgen receptor), androgen receptor signaling was shown to be required for the vitamin Dmediated growth inhibition of the cancer cells (16) . This sets up a paradox of androgens being associated with higher risk for cancer development, but at the same time being important for the anticancer activities of vitamin D.
Located on chromosome 12q13-q14, the high-affinity nuclear vitamin D receptor (VDR) gene mediates most of the biological activity of vitamin D (17) . If vitamin D can regulate the growth of normal and cancerous prostate cells, then variations in the activity of the VDR may be important in the onset and progression of prostate cancer. Two of the commonly studied VDR polymorphisms, FokI and CDX2, result in functional changes. The FokI (T/C) variant alters the translation start site resulting in two isoforms of the VDR protein with differing activities (18) , with the protein product from the FokI T form exhibiting less transcriptional activation than the product from the wild-type C form (19) . The presence of the FokI C allele was found to affect immune cell behavior resulting in a more active immune system (20) . The CDX2 variant in the promoter region of the VDR modulates promoter activity, and the CDX2 G allele, the most common allele, shows 30% less transcriptional activity compared with the A allele (21) . Several studies of the FokI polymorphism and its association with prostate cancer have produced inconsistent results and a metaanalysis of several VDR polymorphisms concluded that FokI was unlikely to have a major role in prostate cancer (22) . CDX2 has been less extensively studied but it was found to increase the risk for prostate cancer in men with the heterozygous genotype and high UV-B exposure (23) .
The gene that codes for 5a-reductase type II, SRD5A2, located on chromosome 2, has several polymorphisms that have been studied for their relationship with prostate cancer. The most common polymorphism is V89L, which substitutes valine at codon 89 with leucine by a C to G nucleotide transversion. The leucine allele (L) reduces 5a-reductase activity resulting in lower DHT levels (24, 25) . The A49T polymorphism results in a threonine substitution for alanine and is associated with increased 5a-reductase activity in vitro causing increased DHT production that may contribute to prostate cancer development or progression (26) . The relationship of the V89L and A49T polymorphisms with prostate cancer has not been proven conclusively. A meta-analysis of SRD5A2 polymorphisms concluded that the V89L polymorphism likely has no, or little, relationship to prostate cancer risk and that A49T may have a modest effect, accounting for only a small proportion of prostate cancer (27) .
Because of the complex etiology of prostate cancer, the effects of many individual genetic polymorphisms are likely to be small. It is possible that larger effects may only be observed when polymorphisms are considered in combination. A polygenic model incorporating multiple loci might maximize the detection of individuals at high risk for prostate cancer (28) .
The current study tested possible interactions of the VDR and SRD5A2 genes as identified by two functional polymorphisms in each gene in determining risk for prostate cancer in a cohort of non -Hispanic White (NHW) and Hispanic White (HW) men from South Texas. The a priori hypotheses of this study were that the FokI T allele and the CDX2 G allele, which both result in decreased vitamin D receptor activity, in combination with the V89L V or A49T T alleles, which result in higher levels of DHT, would lead to increased risk for prostate cancer. Although DHT is important for vitamin D activity and higher DHT levels might be hypothesized to reduce risk by increasing vitamin D levels, we believe that the less efficient vitamin D receptor as indicated by the presence of the FokI T and CDX2 G alleles will not use the higher vitamin D levels to counter the increased risk posed by higher DHT levels.
Materials and Methods
Study population. Study participants came from the populationbased prospective San Antonio Biomarkers of Risk (SABOR) for prostate cancer cohort study at the University of Texas Health Sciences Center at San Antonio, San Antonio, TX (29) . SABOR began enrolling men in May 2001 to examine differences in risk for prostate cancer by race/ ethnicity. Three racial/ethnic groups reflecting the diversity of the Southern Texas population were enrolled: NHW, HW, and African Americans. Only NHW and HW men were used in this study due to limited numbers of African American men (less than 65 prostate cancer cases). Race is self-identified and Hispanic ethnicity was assigned using the Hazuda model for the identification of Mexican Americans and other Hispanic ethnicities (30) . The Hispanic population of South Texas is f95% Mexican American. All participants consented to the genetic studies in accordance with the rules and regulations of the Institutional Review Board of University of Texas Health Sciences Center at San Antonio.
Cases in this analysis were men with histologically confirmed prostate cancer in the SABOR cohort, as well as men diagnosed with confirmed prostate cancer from the same clinics and health fairs from which the SABOR cohort was recruited. Gleason scores (range 2-10) were determined from chart reviews. High-grade cancers were defined as cases with Gleason scores of z7. Prostatectomy scoring was used preferentially over biopsy scores when available.
Controls, selected from the SABOR cohort, were eligible for this analysis if they had prostate-specific antigen values of <2.5 ng/mL at all visits (up to five annual visits) and a normal digital rectal exam at all visits. Age, defined as age at diagnosis for the cases and age at last visit for the controls, was truncated at z45 years old for both cases and controls. The study population consisted of 1,346 men for a total of 585 cases and 761 controls. HW men accounted for 44% of the study sample. Polymorphism selection and genotyping. Two VDR polymorphisms and two SRD5A2 polymorphisms were genotyped: CDX2 (rs17883968; G/A) in the VDR promoter region and FokI (rs10735810; C/T) in VDR exon 2, and V89L (rs523349) and A49T (rs9282858) in exon 1 of the SRD5A2 gene.
DNA for genotyping was extracted from blood samples using a QIAamp blood kit (Qiagen). Genotyping for CDX2, V89L, and A49T was done with TaqMan allelic discrimination assays using the ABI 7900 HT Sequence Detection System (Applied Biosystems). Originally, a TaqMan assay could not be successfully designed for FokI. This polymorphism was genotyped using endonuclease restriction enzyme digestion. Subsequently, a FokI kit was developed and purchased. To do a quality control check on the original FokI genotyping, 324 men (19% of the sample) were re-genotyped using the TaqMan kit. There was only one discrepancy between the two methodologies for an error rate of 0.3%. Applied to our larger sample of 1,685 men, this means that there were potentially 5 men who were discordant. We feel that this is an acceptable error rate and that the original methodology is validated. All genotyping was done in a molecular genetics laboratory at the University of Texas Health Sciences Center at San Antonio.
Men homozygous for each risk allele in the individual polymorphisms were compared with heterozygotes and homozygotes for the complimentary allele combined. Men homozygous for the VDR CDX2 risk allele (G) were compared with men with AG or AA genotypes. For the SRD5A2 V89L polymorphism, the VV genotype was compared with LL and LV genotypes in all analyses. Due to a limited number of men homozygous for the risk alleles in the VDR FokI and SRD5A2 A49T polymorphisms, the risk genotype was combined with the heterozygous genotype and compared with men homozygous for the complementary allele. Thus, for FokI, the comparison was between TT/CT and CC genotypes, and for A49T, it was between the TT/AT and AA genotypes if any TT genotypes were found.
Statistical analyses. All analyses were stratified according to ethnicity. Associations between genotypes and prostate cancer were assessed by m 2 test (Pearson m 2 with 1 or 2 df) and logistic regression analyses. All logistic regression models included age as a continuous variable. Interactions between VDR and SRD5A2 polymorphisms were tested in the logistic regression analyses by adding an interaction term to the model. Nominal logistic regression was used to test the relationship of the Gleason score groups (low grade, 2-6; and high grade, 7-10) to controls as the referent group. For hypothesis testing, a = 0.05 was used whereas 95% confidence intervals (95% CI) were computed for all relative risk estimates (odds ratios, OR). For NHW men, the study sample size had 80% power (a = 0.05) to detect at least a 25% difference in proportions of genotypes between cases and controls based on published reports of genotype proportions in controls. For HW men, the detectable difference was 35%. Analyses were completed using SAS 9.1 statistical software (SAS Institute, Inc.).
Results
The study sample consisted of 932 NHW men (444 cases and 488 controls) and 414 HW men (141 cases and 273 controls; Table 1 ). Controls were somewhat younger than cases in both ethnic groups. Gleason score distribution was not different between ethnic groups.
Genotype distributions for the individual polymorphisms within each ethnic group did not differ by case-control status (Table 2) . Genotype distributions for controls differed by ethnicity, however, for the VDR FokI and the SRD5A2 V89L polymorphisms. Approximately 13% of NHW controls had the FokI TT genotype compared with 21% of HW controls (P = 0.009). For the V89L polymorphism, 52% and 44% of NHW and HW controls, respectively, had the VV genotype (P = 0.001). The genotype distributions in controls for these polymorphisms do not differ significantly from previously published results (31, 32) . Additionally, CDX2 genotype distributions in NHW controls are similar to what was found earlier (33) . There are no published data on CDX2 for HW men.
All polymorphisms were in Hardy-Weinberg equilibrium within each ethnic group. ORs and 95% CIs for the hypothesized risk genotypes are presented in Table 2 . The SRD5A2 A49T AT genotype was compared with the AA genotype as there were no homozygous TT genotypes in the sample. Only the V89L polymorphism in HW men was marginally significant (VV OR, 0.64; 95% CI, 0.41-0.99; P = 0.05). No significant results were seen with the A49T polymorphism and, given the small number of men with the T allele, no interaction analyses were done with this polymorphism.
Evidence of effect modification of the VDR FokI polymorphism by SRD5A2 V89L was found (logistic regression interaction term, P = 0.02). When the effect of the FokI polymorphism was analyzed by V89L genotype, the previously nonsignificant FokI effect was significant in NHW men (Table 3 ). In men with the V89L VV genotype, men with the FokI TT or CT genotypes were at a 50% increased risk for prostate cancer (OR, 1.53; 95% CI, 1.06-2.23; P = 0.03). There was no evidence of interaction between FokI and V89L in HW men.
There was evidence of effect modification of the VDR CDX2 polymorphism by V89L in HW men (logistic regression interaction term, P = 0.03). Men with the higher-risk V89L VV genotype combined with another higher-risk genotype, the CDX2 GG genotype, to increase risk for prostate cancer. HW men with the CDX2 GG and V89L VV genotypes have more than three times the risk for prostate cancer (CDX2 GG OR, 3.16; 95% CI, 1.39-7.19; P = 0.01; Table 4 ). There was no evidence of interaction in NHW men.
The individual polymorphisms were investigated for their associations with higher Gleason score (the measure of cancer grade). Gleason score is an important predictor of disease progression (34) . Decrease in differentiation as measured by the Gleason grade is related to lack of tissue function and the Gleason score correlates with overall disease-free survival: the higher the score, the more likely that disease will recur (35) . There was no evidence of associations with Gleason grade in HW men or in NHW men (results not shown).
Discussion
This study is one of the few to examine genetic risks for prostate cancer in a group of Hispanic men. Using a population of NHW and HW (largely Mexican American) men from South Texas, we found evidence of interaction between three functional polymorphisms from two genes in the vitamin D and androgen pathways to affect risk for prostate cancer. In NHW men, there was an interaction between the VDR FokI and SRD5A2 V89L polymorphisms to increase risk in men with the FokI TT or CT genotypes and the V89L VV genotype. On the other hand, in HW men, the interaction for increased risk was between the VDR CDX2 GG and V89L VV genotypes. This study examined two genes potentially involved with prostate cancer risk in combination. A polygenic approach may be a more appropriate method to study genetic associations with complex diseases such as cancer (28) . The association of FokI with colon cancer was seen only when analyzed in women with less than 23 CAG repeats in the androgen receptor (36) . The association with prostate cancer aggressiveness of a polymorphism in a gene that codes for an enzyme involved with the degradation of DHT, 3h-hydroxysteroid dehydrogenase type II, is strengthened when analyzed by SRD5A2 V89L genotype (37) .
This study found a heterogeneity of effects according to ethnicity. Neither FokI nor V89L alone were associated with prostate cancer in NHW men, but taken together, the odds for disease were increased by 50% in men with the FokI TT/CT and V89L VV genotypes. No such association was found in HW men. HW men had more than three times the odds of prostate cancer if they had the CDX2 GG and the V89L VV genotypes. Previous studies have also observed the heterogeneity of effects by ethnicity with the FokI polymorphism. For example, a significant trend for increasing waist-to-hip ratio with FokI genotype was found in Hispanic women but not in NHW women (31) .
Differences in linkage disequilibrium to unmeasured genes and/or gene-gene interactions may contribute to the differences found by ethnicity. It is possible that these differences may depend on the different combinations of these genes, or other unmeasured genes, either linked or unlinked to the FokI, CDX2, and V89L polymorphisms. The findings of this study suggest that associations and interactions of the VDR and SRD5A2 polymorphisms may be specific to ethnicity, arguing that research results should be stratified by race or ethnicity.
The association of the SRD5A2 V89L polymorphism with prostate cancer ran counter to our hypothesized effect. We hypothesized that the VV genotype would be associated with increased risk for prostate cancer compared with the LL genotype because the L allele is associated with a moderate reduction in 5a-reductase type II activity resulting in lower DHT levels (24) . A meta-analysis of SRD5A2 polymorphisms, however, concluded that the V89L polymorphism likely has no, or little, relationship to prostate cancer risk (27) . Most of the studies in the meta-analysis were done in NHW or African American men. Information on Hispanic men is sparse. A 2005 study in Southern California found that Hispanics with the LL genotype were at significantly increased risk from prostate cancer compared with men with the VV genotype (OR, 7.3; 95% CI, 1.5-35.5), although this finding is based on only 84 cases and 44 controls, of which only 2 controls had the LL genotype (38) . In the current study, HW men with the SRD5A2 V89L VV genotype had a reduced risk compared with the VL/LL genotypes (OR, 0.64; 95% CI, 0.41-0.99; P = 0.05). There was no association with risk in NHW men. The result in HW men was marginal, however, and may reflect a more limited sample size in HW men. These findings need to be studied in a larger cohort.
In contrast to associations with prostate cancer risk, several studies found that the LL genotype was associated with increased risk for measures of disease severity or progression (37) . For example, the LL genotype was associated with more aggressive disease (39), a poorer prognosis as measured by prostate-specific antigen failure (40) , and by the presence of metastases at the time of diagnosis (41) . Thus, it seems that reduced DHT is associated with increased risk for disease progression (42) .
HW men in this study have a higher proportion of the LL genotype (15%) than NHW men (7%). Thus, it seems that HW men are more likely to have a less efficient SRD5A2 gene and therefore less DHT available. This could partly explain the (46) . The authors hypothesized that this contributes to the lower risk of prostate cancer seen in the Inuits. The cases in the SABOR study are largely prevalent rather than incident cases. Most men who were diagnosed during the up to five annual SABOR exams had probably already developed the disease that only became clinically evident during the increased surveillance as part of their participation in the study. Therefore, it is difficult to discern between markers that are associated with initiation or with progression of the disease. Long-term follow-up is needed to determine which cancer cases will progress. Although Gleason score is an imperfect measure of cancer progression, it can be useful to determine between the high-risk (usually Gleason score 7 and above) versus lower-risk cases. Even though no overall association with Gleason score was observed, the high-risk HW cases were more likely to have the V89L LL genotype (23%) than the low-risk cases (9%); there was no difference in NHW men (6% and 7%, respectively).
The presence of population stratification (genetic subgroups), particularly in HW men, could lead to inaccurate estimates of the genetic effects if the subgroups are not equally distributed between cases and controls. A recent study comparing admixture and substructure in Mexicans and Puerto Ricans, the two largest Hispanic/Latino subgroups in the United States, found population substructure in both groups (47) . However, in their study of asthma, they found that this substructure only confounded their results in Puerto Ricans and not in Mexicans. The effect of population stratification may be important only if the substructure includes populations that have differential risk for the disease of interest and differential distributions of the gene of interest (48) . Mexican Americans, who comprise >90% of the SABOR sample, are primarily made up of European and Native American ancestries. Native Americans are at lower risk for prostate cancer compared with NHW men (49) . Only one of the polymorphisms in the current study has been examined in a native population, the Inuits in Greenland, where the proportion of the higher-activity V89L VV genotype was significantly lower in Inuits compared with Europeans (46) . Depending on the percentage of native admixture in the SABOR Hispanic population and if there are different distributions between cases and controls, there could be an inaccurate estimate of the risk effect for the V89L polymorphism or the other polymorphisms in this study. Although a source of systematic bias has not been identified, a panel of ancestry-informative markers on the SABOR population is being run to study this issue.
This study found evidence that the SRD5A2 V89L polymorphism interacts with the functional VDR FokI and CDX2 polymorphisms to affect risk for prostate cancer in NHW and HW men, respectively. This illustrates the importance of examining multiple genes to understand the genetic risks for prostate cancer and the differences seen according to ethnicity. Additionally, a complex analysis may be necessary to understand a complex disease. Because genomewide linkage studies found strong locus heterogeneity of prostate cancer susceptibility genes (50), prostate cancer is not likely caused by a few genes but by multiple genes from different pathways. Therefore, a more complex analysis looking at interactions between genes rather than a single gene analysis may be necessary to understand complex diseases like prostate cancer.
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